Skip to main content

Market Overview

Lantheus Buys Rights To Fibroblast Activation Protein Targeting Imaging Biomarker

  • Lantheus Holdings Inc (NASDAQ: LNTH) has acquired the exclusive worldwide rights to develop, manufacture and commercialize NTI-1309, a PET oncology imaging agent from Noria Therapeutics Inc.
  • NTI-1309 targets fibroblast activation protein (FAP), a target with potential broad imaging applicability and targeting oncology implications.
  • FAP is overexpressed in the tumor microenvironment, specifically in tumor-associated fibroblasts, which modulates tumor progression and immune response.
  • Under terms of the agreement, Noria will drive the early clinical development of NTI-1309.
  • Upon completing the Phase 1 study, NTI-1309 will be integrated into Lantheus's portfolio of imaging biomarkers.
  • The transaction's terms include an upfront license and development fee to Noria, certain milestone payments, and royalties if NTI-1309 is commercialized.
  • Price Action: LNTH shares are up 10.1% at $21.69 in market trading hours on the last check Tuesday.

Related Articles (LNTH)

View Comments and Join the Discussion!

Posted-In: Medical imaging oncologyBiotech News Health Care Contracts Small Cap General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at